Palisade Bio says Phase 1b study shows early clinical, biomarker gains for PALI-2108 in fibrostenotic Crohn’s disease
Bitget2026/09/28 12:50- Palisade Bio flagged new Phase 1b clinical and translational readouts for PALI-2108 ahead of UEG Week 2026 in Barcelona.
- Results will be presented in the future, including an oral talk on fibrostenotic Crohn’s disease on Oct. 18, 2026.
- Data are set to show early endoscopic improvement, biomarker shifts consistent with PDE4 target engagement, favorable safety, and gut-targeted exposure.
- Separate presentations are expected to indicate rapid clinical response in ulcerative colitis and progress on a biomarker to predict responders.
- PALI-2108 is moving into Phase 2 development in ulcerative colitis and Crohn’s disease as a once-daily oral therapy candidate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Major Crypto ETFs Bled $1.5 Billion While Wall Street Went Dip Shopping
"Big Short" Burry increases short positions on Nasdaq 100 and semiconductors, says Nvidia (NVDA.US) influence may enter a "new paradigm"
"The Big Short" Michael Burry has increased his bearish bets on the Nasdaq 100 Index and semiconductor stocks.
Duan Yongping: Currently will not sell Nvidia, and in the future Jensen Huang may return as a “shadow CEO”
Duan Yongping has made it clear that he will not sell Nvidia and sold a large number of put options on the day the news was released. Nvidia may invite Jensen Huang to serve as an advisor, taking on a “shadow CEO” role to retain his influence, but he would no longer have signing authority. Whether this scenario materializes will likely only become clear after the hearing concludes.
US Research Review - Azenta, Cencora, Stratasys
Crypto prices
More
